Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer

被引:12
|
作者
Schoenherr, Regine M. [1 ]
Kelly-Spratt, Karen S. [1 ]
Lin, ChenWei [1 ]
Whiteaker, Jeffrey R. [1 ]
Liu, Tao [2 ]
Holzman, Ted [1 ]
Coleman, Ilsa [1 ]
Feng, Li-Chia [1 ]
Lorentzen, Travis D. [1 ]
Krasnoselsky, Alexei L. [1 ]
Wang, Pei [1 ]
Liu, Yan [1 ]
Gurley, Kay E. [1 ]
Amon, Lynn M. [1 ]
Schepmoes, Athena A. [2 ]
Moore, Ronald J. [2 ]
Camp, David G., II [2 ]
Chodosh, Lewis A. [3 ]
Smith, Richard D. [2 ]
Nelson, Peter S. [1 ]
McIntosh, Martin W. [1 ]
Kemp, Christopher J. [1 ]
Paulovich, Amanda G. [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
[2] Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA
[3] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA
关键词
Breast cancer; Her2; Mouse; Proteome; Transcriptome; TANDEM MASS-SPECTROMETRY; CYSTEINYL-PEPTIDE ENRICHMENT; LC-MS; STATISTICAL-MODEL; PERFORMANCE; THROUGHPUT; STANDARDS; PROTEINS; SYSTEM; IDENTIFICATIONS;
D O I
10.1002/prca.201000037
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Purpose: We generated extensive transcriptional and proteomic profiles from a Her2-driven mouse model of breast cancer that closely recapitulates human breast cancer. This report makes these data publicly available in raw and processed forms, as a resource to the community. Importantly, we previously made biospecimens from this same mouse model freely available through a sample repository, so researchers can obtain samples to test biological hypotheses without the need of breeding animals and collecting biospecimens. Experimental design: Twelve datasets are available, encompassing 841 LC-MS/MS experiments (plasma and tissues) and 255 microarray analyses of multiple tissues (thymus, spleen, liver, blood cells, and breast). Cases and controls were rigorously paired to avoid bias. Results: In total, 18 880 unique peptides were identified (PeptideProphet peptide error rate <= 1%), with 3884 and 1659 non-redundant protein groups identified in plasma and tissue datasets, respectively. Sixty-one of these protein groups overlapped between cancer plasma and cancer tissue. Conclusions and clinical relevance: These data are of use for advancing our understanding of cancer biology, for software and quality control tool development, investigations of analytical variation in MS/MS data, and selection of proteotypic peptides for multiple reaction monitoring-MS. The availability of these datasets will contribute positively to clinical proteomics.
引用
收藏
页码:179 / 188
页数:10
相关论文
共 50 条
  • [31] HER2/neu expression in relation to clinicopathologic features of breast cancer patients
    Traina, Adele
    Agostara, Biagio
    Marasa, Lorenzo
    Calabro, Maurizio
    Zarcone, Maurizio
    Carruba, Giuseppe
    ESTROGENS AND HUMAN DISEASES, 2006, 1089 : 159 - 167
  • [32] HER2/neu Oncogene Silencing in a Breast Cancer Cell Model Using Cationic Lipid-Based Delivery Systems
    Balgobind, Adhika
    Daniels, Aliscia
    Ariatti, Mario
    Singh, Moganavelli
    PHARMACEUTICS, 2023, 15 (04)
  • [33] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [34] HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
    Blancas, Isabel
    Linares-Rodriguez, Marina
    Martin-Bravo, Celia
    Gomez-Pena, Celia
    Rodriguez-Serrano, Fernando
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10) : 2531 - 2540
  • [35] Exploring lipidomic profiles and their correlation with hormone receptor and HER2 status in breast cancer
    Qian, Xiaojun
    Jin, Xiaolin
    He, Jiaying
    Zhang, Junjing
    Hu, Shan
    ONCOLOGY LETTERS, 2025, 29 (01)
  • [36] HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model
    Tam Nguyen-Hoai
    Kobelt, Dennis
    Hohn, Oliver
    Vu, Minh D.
    Schlag, Peter M.
    Doerken, Bernd
    Norley, Steven
    Lipp, Martin
    Walther, Wolfgang
    Pezzutto, Antonio
    Westermann, Joerg
    ONCOIMMUNOLOGY, 2012, 1 (09) : 1537 - 1545
  • [37] HER2/NEU PROTEIN EXPRESSION IN COLORECTAL CANCER
    Andrews, Nimmy
    Letha, V
    Sankar, S.
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2019, 8 (06): : 341 - 345
  • [38] Towards Sustained Silencing of HER2/neu in Cancer By Epigenetic Editing
    Falahi, Fahimeh
    Huisman, Christian
    Kazemier, Hinke G.
    van der Vlies, Pieter
    Kok, Klaas
    Hospers, Geke A. P.
    Rots, Marianne G.
    MOLECULAR CANCER RESEARCH, 2013, 11 (09) : 1029 - 1039
  • [39] HER2/neu-directed therapy for biliary tract cancer
    Javle, Milind
    Churi, Chaitanya
    Kang, HyunSeon C.
    Shroff, Rachna
    Janku, Filip
    Surapaneni, Rakesh
    Zuo, Mingxin
    Barrera, Christian
    Alshamsi, Humaid
    Krishnan, Sunil
    Mishra, Lopa
    Wolff, Robert A.
    Kaseb, Ahmed O.
    Thomas, Melanie B.
    Siegel, Abby B.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [40] Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer
    Shukla, Shailaja
    Singh, Bhawana Komal
    Pathania, Om Prakash
    Jain, Manjula
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2016, 143 : 52 - 58